You are here

Articles

Oncologystat- CML The Changing Landscape: Interview with Prof. Apperley-Parts 1 and 2

Posted on Thursday, November 25, 2010 - 12:30pm
  CML—The Changing Landscape of Front-line Therapy: Part I: Interview With Dr. Jane Apperley
Read more

ASH 2010 - Orlando

Posted on Tuesday, November 9, 2010 - 12:13pm
Chronic Myeloid Leukemia: An Historical Perspective Michael W. Deininger
Read more

Nature News- Cellular 'alchemy' transforms skin into blood 7/11/2010

Posted on Tuesday, November 9, 2010 - 12:04pm
  Published online 7 November 2010 | Nature | doi:10.1038/news.2010.588
Read more

Advances in the Treatment and Management of Patients With CML: A Nurse's Perspective CE Patricia S. Ault, MSN, RN

Posted on Thursday, October 21, 2010 - 12:54pm
Editor's Note:  Chronic myeloid leukemia (CML) represents approximately 11% of all adult forms of leukemia, and in 2009, approximately 5050 cases were diagnosed in the United...
Read more

Second-Generation BCR-ABL Kinase Inhibitors in CML

Posted on Thursday, October 21, 2010 - 12:07pm
CORRESPONDENCE  Second-Generation BCR-ABL Kinase Inhibitors in CML; N Engl J Med 2010; 363:1672-1675October 21, 2010
Read more

CHMP positive recommendation for use of Tasigna in Newly Diagnosed Ph+ CML

Posted on Saturday, September 25, 2010 - 12:01pm
http://www.ema.europa....
Read more

Changing the Culture of Clinical Trials: Reviving a Failing Effort

Posted on Wednesday, September 22, 2010 - 7:56pm
Changing the Culture of Clinical Trials: Reviving a Failing Effort 2010 Sept 22, Lee Schwartzberg, MD, FACP, Editor-in-Chief Cancer research is in big trouble. Surprised? Take issue with this statement? Yes,...
Read more

NEJM article: “Liberating the NHS” — Another Attempt to Implement Market Forces in English Health Care

Posted on Wednesday, September 22, 2010 - 12:07pm
  Nick Black, M.D.- N Engl J Med 2010; 363:1103-1105September 16, 2010
Read more

New BCR/Abl Inhibitor from Ariad Pharmaceuticals

Posted on Tuesday, September 21, 2010 - 11:26am
Ponatinib (AP24534) Pivotal Trial in Drug-Resistant or Intolerant Chronic Myeloid Leukemia Ariad's new drug for CML is now in clinical trial and has Orphan drug status from FDA and EMA. ...
Read more

Blood Journal-Long-term prognostic significance of early molecular response to imatinib

Posted on Wednesday, August 25, 2010 - 7:45pm
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the international randomized study of interferon versus STI571 (IRIS). an...
Read more

Haematology Times- EHA role of Patient Advocacy

Posted on Monday, July 26, 2010 - 12:17pm
  Patient advocacy in clinical trials- EHA Congress, June 10-13th, 2010, Barcelona—Though recent developments aim to improve the clinical trial process, a group of...
Read more

Discovery suggests possible treatment strategy for aggressive leukemias

Posted on Tuesday, July 20, 2010 - 3:01pm
  Researchers at Duke University Medical Center have identified a mechanism that could explain how patients move into the worst phase of chronic myelogenous leukemia (CML).
Read more

Tasigna Beats Sprycel to First-Line CML Punch

Posted on Monday, July 12, 2010 - 7:13pm
  The Pink Sheet Daily, 2010 Jul 5.  J Merrill
Read more

Bosutinib Induces High Response Rates in Imatinib-Resistant, -Intolerant Patients

Posted on Monday, June 28, 2010 - 8:56pm
Bosutinib Induces High Response Rates in Imatinib-Resistant, -Intolerant Patients Elsevier Global Medical News. 2010 Jun 21, N Osterweil
Read more

Making Expanded Access Programs Work For –Not Against– Your Trial Drug

Posted on Tuesday, June 8, 2010 - 9:48pm
The Pink Sheet Daily. 2010 Jun 7, E Hayes
Read more